Agenus Inc. Class Action Lawsuit - AGEN

The filed complaint alleges that Agenus Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the combination therapy of their immuno-oncology products, botensilimab and balstilimab was less effective than the defendants had led investors to believe; (ii) accordingly, botensilimab and balstilimab’s clinical results, as well as their regulatory and commercial prospects, were overstated; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

In order to be eligible to join the AGEN class action lawsuit, you must have incurred a loss on shares of Agenus purchased during the class period listed above.

If you suffered a loss in Agenus during the relevant time frame or pursuant to the relevant offering(s), you have until November 5, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.